glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results could be 'practice changing' for adults with diabetes, CKD GLP-1 receptor agonists' impact on
Description
The review evaluates these drugs across diverse patient populations, including those with clinically established T2D, obesity, CVD, and CKD
examined how chronic hepatitis B virus (HBV)- related gut microbiota imbalance affects miR-1925p and GLP-1 expression in 2018
What should consumers know about the current regulatory environment
doi: 10.5414/cp201462
Importantly, no studies have yet addressed long-term neurodevelopmental outcomes in exposed offspring, a critical gap given the rising use of these agents among reproductive-age women
